These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 33956804)

  • 1. A phase 1 clinical trial of SP16, a first-in-class anti-inflammatory LRP1 agonist, in healthy volunteers.
    Wohlford GF; Buckley LF; Kadariya D; Park T; Chiabrando JG; Carbone S; Mihalick V; Halquist MS; Pearcy A; Austin D; Gelber C; Abbate A; Van Tassell B
    PLoS One; 2021; 16(5):e0247357. PubMed ID: 33956804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. α1-Antitrypsin derived SP16 peptide demonstrates efficacy in rodent models of acute and neuropathic pain.
    Wang Z; Martellucci S; Van Enoo A; Austin D; Gelber C; Campana WM
    FASEB J; 2022 Jan; 36(1):e22093. PubMed ID: 34888951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, Tolerability, and Effects of a Single Subcutaneous Administration of SP16 - a SERPIN-like, Small Peptide Agonist of the Low-Density Lipoprotein-like Receptor 1- on the Acute Inflammatory Response in Patients With ST-Segment Elevation Myocardial Infarction.
    Van Tassell BW; Wohlford GF; Del Buono MG; Damonte JI; Markley R; Turlington J; Kadariya D; Talasaz A; Ho J; Marawan A; Thomas GK; Austin D; Gineste C; Gelber C; Abbate A
    J Cardiovasc Pharmacol; 2022 Nov; 80(5):672-678. PubMed ID: 35881895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and tolerability of a humanized rabbit monoclonal antibody (SSS07) in healthy adults: Randomized double-blind placebo-controlled single ascending dose trial.
    Liu C; Dong W; Xia L; Lv J; Jiang D; Wang Q; Wang M; Wu M; Miao J; Tao T; Wang D; Zheng L; Su S; Liu L; Fang Y
    Int Immunopharmacol; 2021 Feb; 91():107263. PubMed ID: 33383447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SERPIN-Derived Small Peptide (SP16) as a Potential Therapeutic Agent against HIV-Induced Inflammatory Molecules and Viral Replication in Cells of the Central Nervous System.
    Soler Y; Rodriguez M; Austin D; Gineste C; Gelber C; El-Hage N
    Cells; 2023 Feb; 12(4):. PubMed ID: 36831299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and tolerability of high-dose ulinastatin after 2-hour intravenous infusion in adult healthy Chinese volunteers: A randomized, double-blind, placebo-controlled, ascending-dose study.
    Chen Q; Hu C; Liu Y; Liu Y; Wang W; Zheng H; Rong L; Jia J; Sun S; Yu C; Liu YM
    PLoS One; 2017; 12(5):e0177425. PubMed ID: 28493932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-Density Lipoprotein Receptor-Related Protein-1 Is a Therapeutic Target in Acute Myocardial Infarction.
    Toldo S; Austin D; Mauro AG; Mezzaroma E; Van Tassell BW; Marchetti C; Carbone S; Mogelsvang S; Gelber C; Abbate A
    JACC Basic Transl Sci; 2017 Oct; 2(5):561-574. PubMed ID: 30062170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, tolerability and pharmacokinetics of dalcetrapib following single and multiple ascending doses in healthy subjects: a randomized, double-blind, placebo-controlled, phase I study.
    Derks M; Anzures-Cabrera J; Turnbull L; Phelan M
    Clin Drug Investig; 2011; 31(5):325-35. PubMed ID: 21366361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I, placebo-controlled, randomized, double-blind, single ascending dose-ranging study to evaluate the safety and tolerability of a novel biophysical bronchodilator (S-1226) administered by nebulization in healthy volunteers.
    Green FH; Leigh R; Fadayomi M; Lalli G; Chiu A; Shrestha G; ElShahat SG; Nelson DE; El Mays TY; Pieron CA; Dennis JH
    Trials; 2016 Jul; 17():361. PubMed ID: 27464582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A first-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-06741086, an anti-tissue factor pathway inhibitor mAb, in healthy volunteers.
    Cardinal M; Kantaridis C; Zhu T; Sun P; Pittman DD; Murphy JE; Arkin S
    J Thromb Haemost; 2018 Sep; 16(9):1722-1731. PubMed ID: 29908043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Safety, Tolerability, and Pharmacokinetics Profile of BT-11, an Oral, Gut-Restricted Lanthionine Synthetase C-Like 2 Agonist Investigational New Drug for Inflammatory Bowel Disease: A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Trial.
    Leber A; Hontecillas R; Zoccoli-Rodriguez V; Colombel JF; Chauhan J; Ehrich M; Farinola N; Bassaganya-Riera J
    Inflamm Bowel Dis; 2020 Mar; 26(4):643-652. PubMed ID: 31077582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study.
    Tsimikas S; Viney NJ; Hughes SG; Singleton W; Graham MJ; Baker BF; Burkey JL; Yang Q; Marcovina SM; Geary RS; Crooke RM; Witztum JL
    Lancet; 2015 Oct; 386(10002):1472-83. PubMed ID: 26210642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacology of DP-b99 in healthy volunteers: first administration to humans.
    Rosenberg G; Angel I; Kozak A
    Br J Clin Pharmacol; 2005 Jul; 60(1):7-16. PubMed ID: 15963088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
    Vaughan D; Speed J; Medve R; Andrews JS
    Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamics and safety of the novel selective progesterone receptor modulator vilaprisan: a double-blind, randomized, placebo-controlled phase 1 trial in healthy women.
    Schütt B; Kaiser A; Schultze-Mosgau MH; Seitz C; Bell D; Koch M; Rohde B
    Hum Reprod; 2016 Aug; 31(8):1703-12. PubMed ID: 27288475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years.
    Kisicki JC; Fiske K; Lyne A
    Clin Ther; 2007 Sep; 29(9):1967-79. PubMed ID: 18035196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, pharmacokinetics, pharmacogenomics and QT concentration-effect modelling of the SirT1 inhibitor selisistat in healthy volunteers.
    Westerberg G; Chiesa JA; Andersen CA; Diamanti D; Magnoni L; Pollio G; Darpo B; Zhou M
    Br J Clin Pharmacol; 2015 Mar; 79(3):477-91. PubMed ID: 25223836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARα agonist with moderate PPARγ agonist activity in healthy human subjects.
    Jani RH; Kansagra K; Jain MR; Patel H
    Clin Drug Investig; 2013 Nov; 33(11):809-16. PubMed ID: 24062180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and tolerability of single escalating doses of gabapentin enacarbil: a randomized-sequence, double-blind, placebo-controlled crossover study in healthy volunteers.
    Lal R; Sukbuntherng J; Luo W; Chen D; Vu A; Tovera J; Cundy KC
    Clin Ther; 2009 Aug; 31(8):1776-86. PubMed ID: 19808136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, double-blind, placebo-controlled phase I dose escalation study of Dan Qi Tong Mai tablet in healthy volunteers.
    Gou ZP; Zhang W; Liang XF; Wang Y; Mou JH; Li M; Zhang Y; Feng P
    BMC Complement Altern Med; 2019 Nov; 19(1):336. PubMed ID: 31775729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.